Adjunctive valproic acid for delirium and/or agitation on a consultation-liaison service: A report of six cases

James A. Bourgeois, Alan K Koike, Jamie E. Simmons, Sarah Telles, Christopher Eggleston

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The authors present six cases in which valproate was used in patients seen by a consultation-liaison service (CLS) to manage delirium and/or psychotic agitation. The intravenous (IV) preparation (Depacon, Abbott Laboratories) was used in two nothing by mouth (NPO) patients, while the liquid oral preparation (Depakene, Abbott Laboratories) was used via nasogastric tube (NGT) in the other patients. All of these cases had suboptimal responses and for concerning side effects from conventional therapy with benzodiazepines and for antipsychotics. In all six cases, the CLS use of valproic acid combined with conventional antidelirium medications resulted in improved control of behavioral symptoms without significant side effects from valproic acid. Consultation-liaison psychiatrists should consider the addition of valproic acid to control behavioral symptoms of delirium when conventional therapy is inadequate. This may be especially advisable when problematic side effects result from more conventional psychopharmacological management. Specifically, intravenous valproate sodium may be a viable option for NPO patients.

Original languageEnglish (US)
Pages (from-to)232-238
Number of pages7
JournalJournal of Neuropsychiatry and Clinical Neurosciences
Volume17
Issue number2
DOIs
StatePublished - Jan 1 2005

Fingerprint

Delirium
Valproic Acid
Referral and Consultation
Behavioral Symptoms
Benzodiazepines
Antipsychotic Agents
Psychiatry
Mouth
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Adjunctive valproic acid for delirium and/or agitation on a consultation-liaison service : A report of six cases. / Bourgeois, James A.; Koike, Alan K; Simmons, Jamie E.; Telles, Sarah; Eggleston, Christopher.

In: Journal of Neuropsychiatry and Clinical Neurosciences, Vol. 17, No. 2, 01.01.2005, p. 232-238.

Research output: Contribution to journalArticle

Bourgeois, James A. ; Koike, Alan K ; Simmons, Jamie E. ; Telles, Sarah ; Eggleston, Christopher. / Adjunctive valproic acid for delirium and/or agitation on a consultation-liaison service : A report of six cases. In: Journal of Neuropsychiatry and Clinical Neurosciences. 2005 ; Vol. 17, No. 2. pp. 232-238.
@article{dbf5d52b8196433b85f12499a6680f5a,
title = "Adjunctive valproic acid for delirium and/or agitation on a consultation-liaison service: A report of six cases",
abstract = "The authors present six cases in which valproate was used in patients seen by a consultation-liaison service (CLS) to manage delirium and/or psychotic agitation. The intravenous (IV) preparation (Depacon, Abbott Laboratories) was used in two nothing by mouth (NPO) patients, while the liquid oral preparation (Depakene, Abbott Laboratories) was used via nasogastric tube (NGT) in the other patients. All of these cases had suboptimal responses and for concerning side effects from conventional therapy with benzodiazepines and for antipsychotics. In all six cases, the CLS use of valproic acid combined with conventional antidelirium medications resulted in improved control of behavioral symptoms without significant side effects from valproic acid. Consultation-liaison psychiatrists should consider the addition of valproic acid to control behavioral symptoms of delirium when conventional therapy is inadequate. This may be especially advisable when problematic side effects result from more conventional psychopharmacological management. Specifically, intravenous valproate sodium may be a viable option for NPO patients.",
author = "Bourgeois, {James A.} and Koike, {Alan K} and Simmons, {Jamie E.} and Sarah Telles and Christopher Eggleston",
year = "2005",
month = "1",
day = "1",
doi = "10.1176/jnp.17.2.232",
language = "English (US)",
volume = "17",
pages = "232--238",
journal = "Journal of Neuropsychiatry and Clinical Neurosciences",
issn = "0895-0172",
publisher = "American Psychiatric Publishing Inc.",
number = "2",

}

TY - JOUR

T1 - Adjunctive valproic acid for delirium and/or agitation on a consultation-liaison service

T2 - A report of six cases

AU - Bourgeois, James A.

AU - Koike, Alan K

AU - Simmons, Jamie E.

AU - Telles, Sarah

AU - Eggleston, Christopher

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The authors present six cases in which valproate was used in patients seen by a consultation-liaison service (CLS) to manage delirium and/or psychotic agitation. The intravenous (IV) preparation (Depacon, Abbott Laboratories) was used in two nothing by mouth (NPO) patients, while the liquid oral preparation (Depakene, Abbott Laboratories) was used via nasogastric tube (NGT) in the other patients. All of these cases had suboptimal responses and for concerning side effects from conventional therapy with benzodiazepines and for antipsychotics. In all six cases, the CLS use of valproic acid combined with conventional antidelirium medications resulted in improved control of behavioral symptoms without significant side effects from valproic acid. Consultation-liaison psychiatrists should consider the addition of valproic acid to control behavioral symptoms of delirium when conventional therapy is inadequate. This may be especially advisable when problematic side effects result from more conventional psychopharmacological management. Specifically, intravenous valproate sodium may be a viable option for NPO patients.

AB - The authors present six cases in which valproate was used in patients seen by a consultation-liaison service (CLS) to manage delirium and/or psychotic agitation. The intravenous (IV) preparation (Depacon, Abbott Laboratories) was used in two nothing by mouth (NPO) patients, while the liquid oral preparation (Depakene, Abbott Laboratories) was used via nasogastric tube (NGT) in the other patients. All of these cases had suboptimal responses and for concerning side effects from conventional therapy with benzodiazepines and for antipsychotics. In all six cases, the CLS use of valproic acid combined with conventional antidelirium medications resulted in improved control of behavioral symptoms without significant side effects from valproic acid. Consultation-liaison psychiatrists should consider the addition of valproic acid to control behavioral symptoms of delirium when conventional therapy is inadequate. This may be especially advisable when problematic side effects result from more conventional psychopharmacological management. Specifically, intravenous valproate sodium may be a viable option for NPO patients.

UR - http://www.scopus.com/inward/record.url?scp=85047690226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047690226&partnerID=8YFLogxK

U2 - 10.1176/jnp.17.2.232

DO - 10.1176/jnp.17.2.232

M3 - Article

C2 - 15939979

AN - SCOPUS:85047690226

VL - 17

SP - 232

EP - 238

JO - Journal of Neuropsychiatry and Clinical Neurosciences

JF - Journal of Neuropsychiatry and Clinical Neurosciences

SN - 0895-0172

IS - 2

ER -